Michel Sadelain, MD, PhD, is the Stephen and Barbara Friedman chair and the founding director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center. He previously served on the board of directors of the American Society of Gene Therapy (2004-2007) and currently serves on the editorial boards of the peer-reviewed scientific journals Molecular Therapy, Human Gene Therapy and Gene Therapy. 

Dr. Sadelain’s research focuses on novel approaches to enhance T cell co-stimulation and function. His clinical program focuses on B cell malignancies, including on-going studies with CD19-targeted T cells in chronic lymphocytic leukemia and upcoming studies in acute leukemia and lymphoma, as well as solid tumors, including upcoming studies in metastatic prostate cancer.